Spectrum Pharma buy reiterated by Jefferies
Jefferies Group LLC reissued their buy rating on shares of Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) in a report issued on Thursday morning. Jefferies Group LLC currently has a $8.50 price target on the biotechnology company’s stock.
Several other research firms have also recently commented on SPPI. Zacks Investment Research cut shares of Spectrum Pharmaceuticals from a hold rating to a sell rating in a research report on Wednesday, January 11th. FBR & Co set a $11.00 price objective on shares of Spectrum Pharmaceuticals and gave the company a buy rating in a report on Saturday, March 11th. Finally, HC Wainwright set a $10.00 price objective on shares of Spectrum Pharmaceuticals and gave the company a buy rating in a report on Saturday, March 11th. One analyst has rated the stock with a sell rating and four have given a buy rating to the stock. The stock currently has an average rating of Buy and a consensus price target of $8.80.